Vaccine Lyophilization Stabilization with HSA and Mannitol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccines, particularly those for flaviviruses, face challenges in maintaining stability and efficacy during shipment and storage, which affects their potency and durability.
Innovation Solution
A freeze-dried composition comprising a live, attenuated flavivirus vaccine, human serum albumin (HSA) as a stabilizer, lactose and amorphous mannitol as bulking agents, and one or more buffer components, such as histidine and potassium glutamate, is developed to enhance stability and maintain efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccines are stored and shipped in liquid form, then they remain easily accessible and simple to administer, but they lose stability and efficacy under varying temperature conditions
Solution Approach 1:
The vaccine formulation undergoes a parameter change from liquid to frozen state through lyophilization (freeze-drying). This transforms the physical state and moisture content parameters, enabling the vaccine to maintain stability across a broader temperature range during storage and shipping while preserving immunogenicity upon reconstitution
Solution Approach 2:
The invention creates a composite frozen formulation by combining the vaccine antigen with cryoprotectants (such as sugars, proteins, or polymers) and buffers. This composite structure protects the vaccine components during freezing and thawing cycles, maintaining reliability under varying storage conditions
2Reliability
If vaccines are lyophilized to improve stability, then storage temperature range expands and transport becomes easier, but the formulation complexity and processing requirements increase
Solution Approach 1:
The lyophilization process is segmented into distinct stages: freezing, primary drying (sublimation), and secondary drying. Each stage is optimized independently with specific temperature, pressure, and time parameters, allowing complex formulation requirements to be managed through systematic process segmentation
Solution Approach 2:
The formulation parameters are specifically adjusted to optimize lyophilization performance, including selecting cryoprotectants that form stable glass matrices, adjusting pH and ionic strength, and controlling freeze-drying cycle parameters to achieve the desired frozen state structure that maintains vaccine stability
3Adaptability or versatility
If vaccines are lyophilized to expand storage temperature range, then transport and distribution become easier, but titer loss may occur during the freeze-drying process
Solution Approach 1:
Cryoprotectants are incorporated into the formulation beforehand to cushion and protect the vaccine antigen during the freeze-drying process. These protective agents (such as sucrose, trehalose, gelatin, or hydroxyethyl starch) prevent denaturation and aggregation, minimizing titer loss while enabling the expanded storage temperature range
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation and lyophilization process result in a stable vaccine product with minimal titer loss, even at elevated temperatures, ensuring the vaccine remains effective throughout its storage and usage life.
Implementation Method 1
Lyophilization is an approach involved in the processing of some vaccine products, and is essentially a freeze-drying process that, under low pressures, removes water through sublimation
Implementation Method 2
Lyophilization is an approach involved in the processing of some vaccine products, and is essentially a freeze-drying process
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This invention provides pharmaceutical compositions, such as vaccines, and methods of making and using such compositions.